Adalimumab originator and biosimilars in global inflammatory bowel disease treatment

被引：0
|
作者：
Yiu, Tsz Hong [1 ]
Nakase, Hiroshi [3 ]
Leung, Wai Keung [4 ]
Lin, Huiyu [5 ]
Banerjee, Rupa [6 ,7 ]
Anderson, Emilia [2 ]
Leong, Rupert [2 ]
机构：
[1] Western Hlth, Melbourne, Vic, Australia
[2] Concord Repatriat Gen Hosp, Sydney, NSW, Australia
[3] Sapporo Med Univ, Sapporo, Hokkaido, Japan
[4] Univ Hong Kong, Pok Fu Lam, Hong Kong, Peoples R China
[5] Tan Tock Seng Hosp, Singapore, Singapore
[6] Asian Inst Gastroenterol, Gachibowli, India
[7] AIG Hosp, Gachibowli, India
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
101
引用
收藏
页码：173 / 174
页数：2
相关论文
共 50 条
  • [1] Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia
    Anderson, Emilia
    Waller, Karen
    Tamilarasan, Aravind Gokul
    Lin, Huiyu
    Paramsothy, Sudarshan
    Leong, Rupert W.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (08) : 819 - 825
  • [2] NON-MEDICAL SWITCH BETWEEN ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS - A MULTICENTRE STUDY ON EFFICACY AND DRUG SUSTAINABILITY
    Lontai, Livia
    Gonczi, Lorant
    Balogh, Fruzsina
    Komlodi, Nora
    Resal, Tamas
    Farkas, Klaudia
    Molnar, Tamas
    Miheller, Pal
    Golovics, Petra A.
    Schafer, Eszter
    Szamosi, Tamas
    Ilias, Akos
    Lakatos, Peter L.
    GASTROENTEROLOGY, 2022, 162 (07) : S606 - S606
  • [3] Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients - a multicentre study on efficacy and drug sustainability
    Lontai, L.
    Gonczi, L.
    Balogh, F.
    Komlodi, N.
    Resal, T.
    Farkas, K.
    Molnar, T.
    Golovics, P.
    Schafer, E.
    Szamosi, T.
    Miheller, P.
    Ilias, A.
    Lakatos, P. L.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I518 - I519
  • [4] Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo, Marjorie
    Fiorino, Gionata
    Gilardi, Daniela
    Furfaro, Federica
    Roda, Giulia
    Loy, Laura
    Allocca, Mariangela
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (01) : 7 - 12
  • [5] Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients - a multicentre study on efficacy and drug sustainability
    Lontai, L.
    Gonczi, L.
    Balogh, F.
    Komlodi, N.
    Resal, T.
    Farkas, K.
    Molnar, T.
    Golovics, P.
    Schafer, E.
    Szamosi, T.
    Miheller, P.
    Ilias, A.
    Lakatos, P. L.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I518 - I519
  • [6] Biosimilars for the Treatment of Inflammatory Bowel Disease
    Rudrapatna, Vivek A.
    Velayos, Fernando
    PRACTICAL GASTROENTEROLOGY, 2019, 43 (04) : 84 - 91
  • [7] Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study
    Lontai, Livia
    Gonczi, Lorant
    Balogh, Fruzsina
    Komlodi, Nora
    Resal, Tamas
    Farkas, Klaudia
    Molnar, Tamas
    Miheller, Pal
    Golovics, Petra A.
    Schafer, Eszter
    Szamosi, Tamas
    Ilias, Akos
    Lakatos, Peter L.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (12) : 1639 - 1645
  • [8] Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis
    Phan, Duc Binh
    Bewley, Anthony P.
    Laws, Philip
    Mackenzie, Teena
    Smith, Catherine H.
    Griffiths, Christopher E. M.
    Lunt, Mark
    Warren, Richard B.
    Yiu, Zenas Z. N.
    JAMA DERMATOLOGY, 2025,
  • [9] Adalimumab for the treatment of inflammatory bowel disease
    Wasan, Sharmeel K.
    Kane, Sunanda V.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 5 (06) : 679 - 684
  • [10] Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
    Tarsi, Antonio
    Mocci, Giammarco
    Cuomo, Antonio
    Ferronato, Antonio
    Elisei, Walter
    Picchio, Marcello
    Maconi, Giovanni
    Scaldaferri, Franco
    Papa, Alfredo
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2022, 31 (04) : 411 - 416
12345